Condition
Induction Therapy clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Induction Therapy clinical trials that are recruiting, at sites in 2 countries (most in China (4), France (1)). By phase: Phase 2 (4), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 2Countries
Newest Induction Therapy clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| QL1706 with chemotherapy induction followed by immunotherapy consolidation in limited-stage SCLC after chemoradiotherapy | Phase 2 | Shanghai | Recruiting | Jul 29, 2025 |
| Iparomlimab/Tuvorlimab (QL1706) plus modified TPF induction for locally advanced nasopharyngeal carcinoma | Phase 2 | Xiamen, Fujian | Recruiting | Jul 25, 2025 |
| Comparing two and three cycles of chemotherapy with immunotherapy for advanced nasopharyngeal cancer | Phase 2 | Xiamen, Fujian and 2 other locations | Recruiting | Feb 6, 2025 |
| Combining immunotherapy and chemoradiotherapy for esophageal cancer treatment | Phase 2 | Anyang, Henan and 2 other locations | Recruiting | May 20, 2024 |
| Induction in sensitized kidney transplant recipients without pre-existing donor-specific antibodies | Phase 3 | Tours | Recruiting | May 23, 2022 |
All recruiting trials (5)
-
QL1706 with chemotherapy induction followed by immunotherapy consolidation in limited-stage SCLC after chemoradiotherapy
This study tests if QL1706 given with chemotherapy induction can improve outcomes for adults with limited-stage small cell lung cancer after chemoradiation, with follow-up immunotherapy consolidation and biomarker analysis.
-
Iparomlimab/Tuvorlimab (QL1706) plus modified TPF induction for locally advanced nasopharyngeal carcinoma
This trial will test whether adding the dual-antibody Iparomlimab/Tuvorlimab (QL‑1706) to a modified TPF chemotherapy regimen as induction therapy helps adults with newly diagnosed, locally advanced nasopharyngeal carcinoma.
-
Comparing two and three cycles of chemotherapy with immunotherapy for advanced nasopharyngeal cancer
This study is testing whether two cycles of chemotherapy combined with immunotherapy can help people with advanced nasopharyngeal cancer just as much as three cycles, but with fewer side effects.
-
Combining immunotherapy and chemoradiotherapy for esophageal cancer treatment
This study is testing if combining a new immunotherapy drug with traditional chemoradiotherapy can help people with advanced esophageal cancer have better treatment results.
-
Induction in sensitized kidney transplant recipients without pre-existing donor-specific antibodies
This trial tests whether basiliximab or rabbit anti-thymocyte globulin (rATG) work better as induction therapy for adults awaiting kidney transplant who have anti-HLA antibodies but no donor-specific antibodies.
Related topics
Quick answers
How many Induction Therapy clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (4 trials), France (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 4, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.